CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
DSXS topicaldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02932878
NCT02932878Phase 2Completed
CompareCT.gov

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis

Sun Pharmaceutical Industries, Inc.·interventional·Posted Oct 13, 2016·Updated Dec 6, 2018

In Brief

A Phase 2 clinical trial evaluating DSXS topical for Plaque Psoriasis. Completed, enrolled 16 participants across 1 site.

Detailed Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 13, 2016
Enrollment StartSep 2, 2016
Primary CompletionApr 10, 2017
Study CompletionOct 16, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.7 years ago

Interventions

DSXS topicaldrug

topical treatment